Melton landed enough money to start a separate lab, and he works on turning his stem line into insulin-producing cells to study where they go wrong in diabetics.
It is no excuse either for the HP board to have gambled its future on growth by acquisition to stem the way its old-line core businesses, like storage and enterprise software, were collapsing.